MedKoo Cat#: 406750 | Name: ML-347
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML-347, also known as LDN193719, is a potent and selective bone morphogenetic protein receptor (BMP) inhibitor that inhibits ALK1 and ALK2 with IC50 values of 46 and 32 nM, respectively. ML347 shows >300-fold selectivity for ALK2.

Chemical Structure

ML-347
ML-347
CAS#1062368-49-3

Theoretical Analysis

MedKoo Cat#: 406750

Name: ML-347

CAS#: 1062368-49-3

Chemical Formula: C22H16N4O

Exact Mass: 352.1324

Molecular Weight: 352.40

Elemental Analysis: C, 74.98; H, 4.58; N, 15.90; O, 4.54

Price and Availability

Size Price Availability Quantity
10mg USD 300.00 2 Weeks
25mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ML-347; ML347; ML 347; LDN193719; LDN-193719; LDN 193719.
IUPAC/Chemical Name
5-(6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline
InChi Key
FVRYPYDPKSZGNS-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3
SMILES Code
COC1=CC=C(C(C=N2)=CN3C2=C(C4=CC=CC5=C4C=CC=N5)C=N3)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor.
In vitro activity:
The potency contributions of several 3-position substituents were evaluated with subtle structural changes leading to significant changes in potency. From these studies, a novel 5-quinoline molecule was identified and designated an MLPCN probe molecule, ML347, which shows >300-fold selectivity for ALK2 and presents the community with a selective molecular probe for further biological evaluation. Reference: Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. https://pubmed.ncbi.nlm.nih.gov/23639540/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF 5.0 14.19
DMSO 9.3 26.28
DMSO:PBS (pH 7.2) (1:2) 0.3 0.71
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 352.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang H, Zhan Y, Zhang Y, Yuan G, Yang G. Dual roles of TGF-β signaling in the regulation of dental epithelial cell proliferation. J Mol Histol. 2021 Feb;52(1):77-86. doi: 10.1007/s10735-020-09925-1. Epub 2020 Nov 18. PMID: 33206256. 2. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. doi: 10.1016/j.bmcl.2013.03.113. Epub 2013 Apr 11. PMID: 23639540; PMCID: PMC3677712.
In vitro protocol:
1. Zhang H, Zhan Y, Zhang Y, Yuan G, Yang G. Dual roles of TGF-β signaling in the regulation of dental epithelial cell proliferation. J Mol Histol. 2021 Feb;52(1):77-86. doi: 10.1007/s10735-020-09925-1. Epub 2020 Nov 18. PMID: 33206256. 2. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. doi: 10.1016/j.bmcl.2013.03.113. Epub 2013 Apr 11. PMID: 23639540; PMCID: PMC3677712.
In vivo protocol:
TBD
1: Engers DW, Frist AY, Lindsley CW, Hong CH, Hopkins CR. Development of a potent and ALK2 selective bone morphogenetic protein receptor (BMP) inhibitor. 2013 Apr 12 [updated 2014 Sep 18]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK259191/ PubMed PMID: 25506972. 2: Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. doi: 10.1016/j.bmcl.2013.03.113. Epub 2013 Apr 11. PubMed PMID: 23639540; PubMed Central PMCID: PMC3677712.